Literature DB >> 1423878

Inhibition of mouse skin tumorigenesis by dexamethasone occurs through a Ha-ras-independent mechanism.

J M Strawhecker1, J C Pelling.   

Abstract

The Ha-ras oncogene has been shown to be point-mutated and overexpressed in papillomas induced by the two-stage skin tumorigenesis regimen of 7,12-dimethylbenz[a]anthracene (DMBA) and promotion with 12-O-tetradecanoylphorbol-13-acetate (TPA). Glucocorticoids inhibit mouse skin tumorigenesis when applied with the initiation agent or with the promoting agent. We have extended these studies to evaluate whether dexamethasone (Dex) treatment could inhibit development of already established tumors. An additional objective of this study was to investigate whether glucocorticoids directly inhibit Ha-ras gene expression at the level of transcription during skin tumorigenesis. In this report we demonstrate that topical Dex treatments significantly suppressed the formation of additional tumors relative to the acetone control group. However, Northern blot analysis of total RNA isolated from representative tumors during a series of sequential weeks of promotion indicated that Dex did not have a direct effect on Ha-ras steady-state mRNA levels despite the decrease in additional tumor numbers in the Dex-treated groups. We also investigated short-term effects of Dex on endogenous Ha-ras expression in normal mouse epidermis. Topical Dex administration had no effect on endogenous Ha-ras steady-state mRNA levels in normal skin after 2 or 24 h. To ensure that endogenous corticosterone levels in the SENCAR mouse were not influencing our results, Ha-ras mRNA levels in epidermis from SENCAR mice adrenalectomized 48 h prior to being killed were compared to Ha-ras levels in normal epidermis by Northern blot analysis. The data from this analysis revealed that bilateral adrenalectomy had no effect on Ha-ras steady-state mRNA levels in epidermis compared to ras levels in normal mouse epidermis. In summary, our results demonstrate that although Dex can inhibit further tumor development in DMBA/TPA-treated mouse epidermis, it does not do so by directly effecting Ha-ras gene expression in mouse epidermis.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1423878     DOI: 10.1093/carcin/13.11.2075

Source DB:  PubMed          Journal:  Carcinogenesis        ISSN: 0143-3334            Impact factor:   4.944


  6 in total

1.  The possible separation of 12-O-tetradecanoylphorbol-13-acetate-induced skin inflammation and hyperplasia by compound A.

Authors:  Piotr Kowalczyk; Magdalena C Kowalczyk; Jacob J Junco; Olga Tolstykh; Tatsuya Kinjo; Ha Truong; Zbigniew Walaszek; Margaret Hanausek; Thomas J Slaga
Journal:  Mol Carcinog       Date:  2012-02-21       Impact factor: 4.784

Review 2.  Oncogenes as inducers of tumor angiogenesis.

Authors:  J Rak; J Filmus; G Finkenzeller; S Grugel; D Marmé; R S Kerbel
Journal:  Cancer Metastasis Rev       Date:  1995-12       Impact factor: 9.264

3.  IL-13 but not IL-4 signaling via IL-4Rα protects mice from papilloma formation during DMBA/TPA two-step skin carcinogenesis.

Authors:  Michael Rothe; David Quarcoo; Anna A Chashchina; Svetlana V Bozrova; Zhihai Qin; Sergei A Nedospasov; Thomas Blankenstein; Thomas Kammertoens; Marina S Drutskaya
Journal:  Cancer Med       Date:  2013-10-22       Impact factor: 4.452

Review 4.  Selective glucocorticoid receptor-activating adjuvant therapy in cancer treatments.

Authors:  Nora Sundahl; Dorien Clarisse; Marc Bracke; Fritz Offner; Wim Vanden Berghe; Ilse M Beck
Journal:  Oncoscience       Date:  2016-07-27

5.  Role of AMPK and PPARα in the anti-skin cancer effects of ursolic acid.

Authors:  Jacob J Junco; Jiyoon Cho; Anna Mancha; Gunjan Malik; Sung-Jen Wei; Dae Joon Kim; Huiyun Liang; John DiGiovanni; Thomas J Slaga
Journal:  Mol Carcinog       Date:  2018-09-19       Impact factor: 4.784

6.  A transition in transcriptional activation by the glucocorticoid and retinoic acid receptors at the tumor stage of dermal fibrosarcoma development.

Authors:  M D Vivanco; R Johnson; P E Galante; D Hanahan; K R Yamamoto
Journal:  EMBO J       Date:  1995-05-15       Impact factor: 11.598

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.